Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06580574
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-24
Brief Title:
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMRMSI-H Gastric or Colon Cancers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Sintilimab With Selective Combination of Sintilimab IBI310 and Lenvatinib Used for Organ Preservation in Non-metastatic Gastric or Colon Cancers With Mismatch Repair Deficiency or High Microsatellite Instability
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to explore the role of PD1PDL1 antibody with selective combination of Sintilimab IBI310 and Lenvatinib in organ preservation in non-metastatic dMMRMSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None